Lucio et al. have devised a strategy consisting of cisplatin-conjugated SWCNHs attached to an antibody against PSMA-positive prostate cancer cells to promote a selective binding and uptake of the conjugate by positive PSMA cells without reporting any effect on negative PSMA cells [79]. This evidence concerns the gene FOLH1 and prostate carcinoma.